Nautilus Biotechnology, Inc. (NAUT) is a Technology stock trading at $0.90 (as of 2026-08-20), with a market capitalization of $114.35M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Nautilus Biotechnology, Inc. is a development-stage life sciences company developing platform technology for measuring and analyzing the proteome. Its Nautilus Platform provides an end-to-end solution that includes instruments, consumables, and software analysis for proteomics workflows.
| Price | $0.90 |
| Market Cap | $114.35M |
| Price / Book | 0.79 |
| FCF Yield | -46.3% |
| Sector P/E (Technology) | 33.9 |
| Industry P/E (Measuring & Control Equipment) | 51.8 |
| Top Institutional Holder | a16z Capital Management, L.L.C. ($68.50M) |
| Institutional Holders Tracked | 10 |
| Sector | Technology |
| Industry | Measuring & Control Equipment |
| CEO | Sujal Patel |
| Employees | 134 |
| Country | US |
| IPO Date | 2020-08-07 |
Data as of 2026-08-20.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.